A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.
about
Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer developmentPopulation pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACSPopulation pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseEffect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody.Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.T cell targeted immunotherapy for autoimmune disease.Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Therapeutic targets for rheumatoid arthritis: Progress and promises.Drug Development of Therapeutic Monoclonal Antibodies.Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.Construction of Macaque Immune-Libraries.Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.Population pharmacokinetic-pharmacodynamic modeling of biological agents: when modeling meets reality.
P2860
Q31148686-23068A50-9FA1-427B-8014-8E9169C069A6Q33708140-6D552DA0-99D5-4578-827A-2346098FDC29Q35826428-9C9C54C2-E3FB-4E7D-88EE-A02F9F6D3268Q36024673-21C55534-E0AD-4260-A4A1-806710CF13FBQ36214426-C0F6E5A7-0DFB-4BF2-A6DA-A13A2C49914DQ36269613-1A75B9CA-965F-4062-94A3-CF69F72F114DQ36359571-DE579194-C223-47DE-A30D-878D0F5DAE0EQ37510861-C72D6DE3-824A-4773-89FF-EE747F7A4115Q37810155-55DE5CF1-B6DB-4C27-8C16-1EC1CE15CFC5Q38072598-59E0F3A8-FA93-4B92-B408-22E18B15D5D5Q38179461-149FE065-936E-466F-90DA-FD847BE939ADQ38876360-C4BDBBCA-E2F8-41D4-83E0-058D5449B6CEQ38962519-FA419773-64AB-475C-BC89-B82D1A3D8249Q46412325-7EFD1D15-908E-4CB9-BC18-448C10E65751Q47369432-B16D5BBE-45EB-4258-B107-8B858314CF7AQ51896176-2976C460-2792-4D43-9955-BF3705774CA9Q53074587-80DC643C-6B2D-4845-B41C-7B171F0984E8
P2860
A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
A population pharmacokinetic-p ...... nts with rheumatoid arthritis.
@en
type
label
A population pharmacokinetic-p ...... nts with rheumatoid arthritis.
@en
prefLabel
A population pharmacokinetic-p ...... nts with rheumatoid arthritis.
@en
P2093
P2860
P1476
A population pharmacokinetic-p ...... nts with rheumatoid arthritis.
@en
P2093
Elliott MJ
Minthorn EA
Totoritis MC
P2860
P304
P356
10.1016/S0009-9236(99)70032-9
P407
P577
1999-09-01T00:00:00Z